“There’s plenty of room for improvement. If Lilly can build a better mousetrap, it could be a big seller for them.”
Turn on your television, and there’s a good chance you’ll see lots of people tossing and turning in bed, unable to get to sleep without a pill. via The Indianapolis Star
From Insomnia News
“I think this could be a very, very important medicine, and thus a very important product for our company.”
Turn on your television, and there’s a good chance you’ll see lots of people tossing and turning in bed, unable to get to sleep without a pill. via IndyStar.com
From Insomnia News
Actelion Ltd announced today that the company has initiated the comprehensive Phase III program RESTORA with its first-in-class orexin receptor antagonist, almorexant. via PrimeNewswire
From Insomnia News
The Portland Clinic has opened a new sleep center at its 6640 S.W. Redwood Lane medical office in Portland. via Portland Business Journal
From Insomnia News
“There is some evidence from smaller studies, like one that looked at twins, that suggests a genetic factor”
Go to sleep at the same time every night and wake up at the same time each morning. via USA Today
From Insomnia News
In a decision that Neurocrine described as “disturbing,” “totally unanticipated,” and “unprecedented” in a conference call, the FDA decided to issue Neurocrine’s insomnia treatment indiplon a second approvable … via Fool.com
From Insomnia News
“Overall, I think the FDA is in a difficult spot with Vioxx and safety issues. But several of their questions didn’t even necessarily focus on safety”
Neurocrine Biosciences said yesterday that its insomnia drug failed to win regulatory approval, sending shares down 50 percent to an eight-year low. via San Diego Union-Tribune
From Insomnia News
“This is the final nail in the coffin toward its development”
Neurocrine scientists will pull all-nighters to gather additional data on its latest insomnia treatment. via Forbes.com
From Insomnia News
“It’s actually a single observation in a single species that may very well be species-specific.”
LONDON : GlaxoSmithKline said on Thursday its neuroscience drug development programme had made significant advances, although a closely watched experimental insomnia drug has been put on voluntary hold. via International Herald Tribune
From Insomnia News
Many people suffering from insomnia are looking for ways to overcome their problem, or at least get some relief from it. via Buzzle.com
From Insomnia News
Sleep Disorder Information
